News

In collaboration with Liverpool John Moores University and AstraZeneca, the team have developed a simple approach to trawl through large databases of pharmaceutical drugs and assess the likely

The deal is structured in three parts, with Celgene paying $1.1bn in cash upfront for Impact Biomedicines, which is currently engaged in the development of fedratinib for the treatment

The Japanese pharma firm said that the deal reinforces its commitment to patients with Inflammatory Bowel Disease (IBD), which currently has limited treatment options. The acquisition will also

The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus

ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involves hundreds of additional repetitions of a six base

Promacta can now be used in combination with standard immunosuppressive therapy to treat the rare blood disorder. SAA is a condition in which the bone marrow of the

CX-01 is an investigational agent that has the potential to enhance the effectiveness of leukemia treatments by disrupting the adhesion of leukemia cells in the protective bone marrow

Upon closing of the acquisition, Viamet Pharmaceuticals will be a portfolio company of NovaQuest Capital, which will focus on further development of VT-1161 and related assets. Viamet Pharmaceuticals

The companies have announced a development strategy for M710, a proposed biosimilar to Eylea injection. Eylea is a vascular endothelial growth factor (VEGF) inhibitor developed to treat neovascular